From Barchart: 2025-02-06 06:24:00

McKesson (NYSE:MCK) shares dropped almost 2% in pre-market trading after reporting Q3 earnings and revenue below analyst expectations. However, the pharmaceutical distributor raised its full-year earnings guidance, showing confidence in its long-term prospects. Adjusted EPS was $8.03, revenue reached $95.29 billion, and the fiscal 2025 EPS guidance was revised upward.

The company’s U.S. Pharmaceutical segment, its biggest revenue driver, saw a 19% increase to $87.1 billion, driven by higher prescription volumes and oncology platform expansion. McKesson also acquired an 80% stake in PRISM Vision Holdings, LLC, to strengthen its presence in vision care services.

Despite missing earnings estimates, McKesson’s revenue growth and strategic acquisitions indicate underlying strength. The company’s revised fiscal 2025 guidance and expansion into vision care suggest a positive outlook for the future.



Read more at Barchart:: McKesson Slips on Q3 Miss but Lifts Full-Year Outl…